| Literature DB >> 28853617 |
Allison Winter1, Lisa Rybicki2, Shetal N Shah3, Deepa Jagadeesh1, Aaron T Gerds1, Betty K Hamilton1, Hien Liu1, Robert Dean1, Ronald Sobecks1, Brad Pohlman1, Mitchell Smith1,4, Matt Kalaycio1, Brian J Bolwell1, Navneet S Majhail1, Brian T Hill1.
Abstract
Pre-transplant PET/CT may be prognostic in diffuse large B-cell lymphoma (DLBCL) patients undergoing autologous stem cell transplantation (ASCT). We reviewed relapsed and pre-transplant PET/CT scans of 32 patients with DLBCL treated with ASCT to determine the Deauville score and the maximum standardized uptake value (SUVmax). Patients with a Deauville score of 4 had a significantly inferior prognosis. The 3-year progression-free survival (PFS) for patients with Deauville 1-3 score was 64%, compared to 0% for Deauville 4, while the 3-year overall survival (OS) was 84% and 25%, respectively (p < .001, p = .002). The change in the SUVmax (>66 versus ≤66%) was not predictive of PFS or OS, but a high pre-transplant SUVmax (>6) demonstrated a trend towards an inferior PFS. Pre-transplant PET/CT is a tool for identifying DLBCL patients at high risk for treatment failure with ASCT and could be used to risk-stratify patients in prospective clinical trials of novel transplant strategies.Entities:
Keywords: Lymphoma and Hodgkin disease; clinical results; prognostication
Mesh:
Substances:
Year: 2017 PMID: 28853617 DOI: 10.1080/10428194.2017.1369065
Source DB: PubMed Journal: Leuk Lymphoma ISSN: 1026-8022